Preclinical Animal Model

Species selection in a preclinical animal model depends on how closely the model reproduces the biological features relevant to the disease or treatment question. Researchers then consider whether the system can support meaningful clinical, physiological, behavioral, or molecular measurements. This alignment helps interpret treatment responses and judge whether findings may inform later translational work.

Clinical, physiological, behavioral, and molecular endpoints provide different views of an intervention's effects. Clinical measures can indicate disease-related changes, while physiological or behavioral observations may capture functional responses. Molecular measurements can examine biological changes associated with treatment or disease. Using these endpoint categories helps researchers evaluate outcomes beyond a single observable effect.

Validity concerns how well a model represents the biological features relevant to the research question, whereas reproducibility concerns whether similar procedures produce dependable findings. Both influence confidence in observed treatment effects, toxicity, pharmacokinetics, or disease progression. Attention to animal welfare is also essential because responsible study design supports the reliability and interpretation of biological results.

Some preclinical animal models are created by inducing relevant biological features, while others reproduce features that already occur within the selected biological system. The distinction affects how researchers interpret disease mechanisms and intervention responses. In either case, the model must be judged by how appropriately its features address the intended question and support informative endpoints.

A typical workflow begins by selecting a suitable species and establishing or identifying the relevant disease features. Researchers then administer or evaluate an intervention under controlled conditions and measure responses using selected clinical, physiological, behavioral, or molecular endpoints. The resulting data can be examined for therapeutic effects, toxicity, pharmacokinetics, and changes in disease progression.

These models can help investigate disease mechanisms, characterize disease progression, and evaluate whether a potential treatment produces a therapeutic response. They can also provide information about toxicity and pharmacokinetics before human studies begin. In biology, this evidence contributes to translational research by connecting controlled laboratory observations with questions about possible human health outcomes.